We aspire to become a world leader in AI-immunology, decoding the human immune system to develop effective immunotherapies for cancer and infectious diseases based on deep biological insights. We believe our ground-breaking AI-Immunology™ models PIONEER™, EDEN™ and RAVEN™, trained to simulate the immune system, can be harnessed to rapidly and cost-effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development. We have two personalized cancer immunotherapies in the clinic and are advancing a portfolio of vaccines to treat bacterial and viral infections. With an experienced management team, strong IP portfolio and scalable business model, Evaxion is well positioned for rapid growth.
Are you eager to deep-dive into Evaxion's business?
Download our company presentation below, or click here to see all our latest presentations.
Feb 20, 2024
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
Feb 07, 2024
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 6, 2024